SIMONI (Smart Integrated Monitoring) as a novel bioanalytical strategy for water quality assessment: Part II-field feasibility survey

Because it is impossible to chemically analyze all relevant micropollutants, the implementation of bioanalytical tools is essential to estimate ecological risks of chemical mixtures in regular water-monitoring programs. The first tier of the Smart Integrated Monitoring (SIMONI) strategy, which was described in part I, is based on the combination of passive sampling and bioanalytical measurements. Bioassay responses are compared with effect-based trigger values (EBT), and an overall SIMONI score on all bioassay data was designed to indicate environmental risks. The present study is focused on analyzing the feasibility of the hazard identification tier by evaluating results of 45 field campaigns at sites with different pollution profiles near the city of Amsterdam. A Daphnia assay was performed in situ, while silicon rubber or polar organic chemical integrative sampler (POCIS) extracts were tested with 4 nonspecific (daphnids, algae, bacteria, and cell culture) and 10 specific (9 Chemical Activated Luciferase Gene Expression [CALUX] assays and antibiotics scan) bioassays. Sensitivity analyses demonstrated the relevance of 2 classification variables in the SIMONI score formula on all bioanalytical data. The model indicated increased risks for the ecosystem at surface waters in greenhouse areas and undiluted wastewater-treatment plant (WWTP) effluents. The choice of testing specific bioassays on either polar or nonpolar passive sampling extracts is cost-effective and still provided meaningful insights on micropollutant risks. Statistical analyses revealed that the model provides a relevant overall impact assessment based on bioassay responses. Data analyses on the chemically determined mixture toxic pressure and bioanalytical methods provided similar insights in relative risk ranking of water bodies. The SIMONI combination of passive sampling and bioanalytical testing appears to be a feasible strategy to identify chemical hazards. Environ Toxicol Chem 2017;36:2400-2416. © 2017 SETAC.

SIMONI (smart integrated monitoring) as a novel bioanalytical strategy for water quality assessment: Part i-model design and effect-based trigger values

It is virtually impossible to reliably assess water quality with target chemical analyses only. Therefore, a complementary effect-based risk assessment by bioanalyses on mixtures of bioavailable micropollutants is proposed: the Smart Integrated Monitoring (SIMONI) strategy. The goal of this strategy is to obtain more reliable information on the water quality to select optimum measures for improvement. The SIMONI strategy is 2-tiered. Tier 1 is a bioanalytical hazard identification of sites. A tier 2 ecological risk assessment is carried out only at a limited number of sites where increased hazards are detected in tier 1. Tier 2 will be customized, based on tier 1 evaluation and additional knowledge of the aquatic system. The present study focuses on the tier 1 bioanalytical hazard identification to distinguish "hot spots" of chemical pollution. First, a selection was made of relevant and cost-effective bioanalytical endpoints to cover a wide spectrum of micropollutant modes of action. Specific endpoints may indicate which classes of chemicals might cause adverse effects. Second, effect-based trigger values (EBT) were derived for these bioassays to indicate potential ecological risks. Comparison of EBT with bioassay responses should discriminate sites exhibiting different chemical hazards. Third, a model was designed to estimate the overall risks for aquatic ecosystems. The associated follow-up for risk management is a "toxicity traffic light" system: green, low hazard (no action required); orange, potential risk (further research needed); and red, high risk (mitigation measures). Thanks to cost-effectiveness, flexibility, and relevance, the SIMONI strategy has the potential to become the first bioanalytical tool to be applied in regular water quality monitoring programs. Environ Toxicol Chem 2017;36:2385-2399. © 2017 SETAC.

Understanding Bone Damage After Kidney Transplantation: A Retrospective Monocentric Cross Sectional Analysis

BACKGROUND

Kidney transplantation (KT) immunosuppression may induce bone tissue damage with bone mineral density (BMD) loss increasing bone fractures risk. Steroid therapy is considered the major player, but others factors are still under review.

PATIENTS AND METHODS

We designed an observational retrospective cohort study to evaluate bone damage after KT. The prevalence of osteopenia, osteoporosis, bone fractures, and the associated risk factors were investigated. The following parameters were recorded before transplantation and at the last follow-up: demographic indexes, cumulative steroid dose (CSD), dialytic and transplantologic age, previous nephropathy, femoral and lumbar BMD, fractures, immunosuppressors, calcemia, phosphoremia, rejection episodes, estimated glomerular filtration rate, and parathyroid hormone and vitamin D levels. Stata software (Stata Corporation, College Station, Texas, United States) was used for the statistical analysis, to perform the Fisher's exact test, Kruskal-Wallis test, Student t test, as well as univariate and multivariate analyses.

RESULTS

The analyzed cohort was composed of 297 patients (65.3% males and 34.7% females). Sixty percent of KT patients had normal BMD, 24% had osteopenia, and 15% had osteoporosis. Twelve percent were victims of bone fractures (8.4% minor, 2% femoral, and 1.7% vertebral). A significant correlation (P <.05) was observed for both osteopenia and osteoporosis with menopause, transplantologic age, CSD, previous glomerulonephritis, and mammalian target of rapamycin (mTOR) inhibitors treatment (imTOR).

CONCLUSION

This study confirms the correlation between CSD (both before and after transplantation) and post-transplantation bone damage. It also shows that a large fraction of these patients had normal BMD related with a low steroid dose in our protocols. This correlation between imTOR assumption and osteoporosis deserves attention and warrants further in vitro analyses to be performed.

Sirolimus prevents short-term renal changes induced by ischemia-reperfusion injury in rats

BACKGROUND

Ischemia-reperfusion (I/R) is present at various degrees in kidney transplants. I/R plays a major role in early function and long-term survival of renal allograft. The purpose of our study was to determine if immunosuppressants modulate I/R in a model that separates I/R from all immune responses.

METHODS

Sprague-Dawley rats with monolateral renal I/R received daily cyclosporine (A), tacrolimus (B), sirolimus (C) or saline (D). Sham-operated rats received saline (E). After 30 days, glomerular filtration rate for each kidney was measured by inulin clearance. Kidney injury was examined, and TGF-β, fibronectin and metalloproteases were evaluated by real-time PCR, Western blot and zymography.

RESULTS

Sirolimus, but not cyclosporine and tacrolimus, prevented a glomerular filtration rate decrease in I/R kidneys (403 ± 303 vs. 1,006 ± 484 μl/min, p < 0.05; 126 ± 170 vs. 567 ± 374 μl/min, p < 0.05; 633 ± 293 vs. 786 ± 255; A, B and C group, respectively, I/R vs. contralateral kidneys). Sirolimus reduced ED-1+ cell infiltrate, interstitial fibrosis and intimal thickening of small vessels observed in I/R kidneys of controls and calcineurin inhibitor-treated rats. Tacrolimus and cyclosporine increased fibronectin and TGF-β expression and matrix deposition. Only sirolimus increased metalloprotease activity.

CONCLUSIONS

Sirolimus but not calcineurin inhibitors prevented I/R-induced kidney injury.

Effects of sirolimus on human mesangial cells

Mesangial cell (MC) proliferation and production of extracellular matrix or loss of MC are both central findings in a number of renal proteinuric diseases. However, the role of MC as components of the glomerular filtration barrier and whether MC alterations induce changes in the glomerular filtration barrier leading to proteinuria are still matters of debate. The effects of Sirolimus (SRL) in proteinuric nephropathies is controversial: some papers have indicated a reduction and others, an increase in proteinuria after sirolimus treatment. Considering the pivotal role of MC in the pathogenesis of many chronic nephropathies, we evaluated the effect of SRL on cultured human MC. We treated primary human MC cultures with SRL, or platelet-derived growth factor (PDGF) or SRL + PDGF, or dimethylsulfoxide, the SRL vehicle, as a control. PDGF was used to activate MC. After 48 hours treatment, MC showed a significant growth increase that was significantly reduced by SRL (P < .01). Apoptosis, determined by the TUNEL assay and flow cytometry, was not modified by the treatments at 24 hours. SRL treatment increased significantly the number of alpha-smooth muscle actin-positive cells compared with controls (P < .05). Cells treated with SRL and SRL + PDGF showed significant changes in morphology with increased mean cell surface, perimeter, and maximum diameter (P < .01) but not protein content. Furthermore, MC treated with SRL showed decreased migration through polycarbonate membranes. The changes induced by SRL may help to explain some of the in vivo effects observed in SRL-treated patients.